Scilex Holding Company

SCLX

$63M

Micro Cap

NASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaPALO ALTO

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Aug 12, 2026

Market Overview

Stock performance and key metrics

SCLX News

Catalyst Timeline

1 upcoming, 0 past

EarningsNext

SCLX Earnings Report

Aug 12, 2026Confirmed

FQ end 2026-06

How SCLX's past catalysts played out

earningsAug 2025+19%earningsMay 2025+7%earningsApr 2025-7%earningsMay 2024+8%earningsMar 2024-6%earningsAug 2023-7%earningsNov 2022-16%

Drug Pipeline

SP-102

Phase 3

Lumbosacral Radicular Pain

SP-103

Phase 2

Moderate to Severe Acute Lower Back Pain

Drug Name	Phase	Indication	Designations	Patent
SP-102	Phase 3	Lumbosacral Radicular Pain	-	-
SP-103	Phase 2	Moderate to Severe Acute Lower Back Pain	-	-

📑

Catalyst DossierPRO

The full research note — thesis, the if-approved scenario, financials & smart money. Compiled by CeliA.

→

Catalyst Verdict

Full breakdown — the signals behind the verdict

Market-Implied Move

Regulatory Approvals

Frequently asked questions

What is in Scilex Holding Company's drug pipeline?→

CatalystAlert tracks 2 drug candidates in Scilex Holding Company's (SCLX) pipeline across Phase 3, Phase 2. Its lead program is SP-102 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is Scilex Holding Company's next FDA catalyst?→

Scilex Holding Company's (SCLX) next tracked catalyst is a Earnings expected August 12, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track SCLX biotech catalysts?→

Add SCLX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Scilex Holding Company's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply